438 related articles for article (PubMed ID: 23756627)
1. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.
Muenst S; Soysal SD; Gao F; Obermann EC; Oertli D; Gillanders WE
Breast Cancer Res Treat; 2013 Jun; 139(3):667-76. PubMed ID: 23756627
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
3. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.
Muenst S; Schaerli AR; Gao F; Däster S; Trella E; Droeser RA; Muraro MG; Zajac P; Zanetti R; Gillanders WE; Weber WP; Soysal SD
Breast Cancer Res Treat; 2014 Jul; 146(1):15-24. PubMed ID: 24842267
[TBL] [Abstract][Full Text] [Related]
4. The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.
Ubago JM; Blanco LZ; Shen T; Siziopikou KP
Am J Clin Pathol; 2019 Jul; 152(2):169-176. PubMed ID: 30984969
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
6. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
Schalper KA; Velcheti V; Carvajal D; Wimberly H; Brown J; Pusztai L; Rimm DL
Clin Cancer Res; 2014 May; 20(10):2773-82. PubMed ID: 24647569
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of tumor-infiltrating lymphocytes in breast cancer.
Stanton SE; Disis ML
J Immunother Cancer; 2016; 4():59. PubMed ID: 27777769
[TBL] [Abstract][Full Text] [Related]
8. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
Noh BJ; Kwak JY; Eom DW
BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
[TBL] [Abstract][Full Text] [Related]
9. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
[TBL] [Abstract][Full Text] [Related]
10. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.
Green AR; Aleskandarany MA; Ali R; Hodgson EG; Atabani S; De Souza K; Rakha EA; Ellis IO; Madhusudan S
Cancer Immunol Res; 2017 Apr; 5(4):292-299. PubMed ID: 28254786
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
Hou Y; Nitta H; Wei L; Banks PM; Lustberg M; Wesolowski R; Ramaswamy B; Parwani AV; Li Z
Breast J; 2018 Nov; 24(6):911-919. PubMed ID: 30230111
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
Jang N; Kwon HJ; Park MH; Kang SH; Bae YK
Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719
[TBL] [Abstract][Full Text] [Related]
13. Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer.
Bae SB; Cho HD; Oh MH; Lee JH; Jang SH; Hong SA; Cho J; Kim SY; Han SW; Lee JE; Kim HJ; Lee HJ
J Breast Cancer; 2016 Sep; 19(3):242-251. PubMed ID: 27721873
[TBL] [Abstract][Full Text] [Related]
14. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
15. Two progressive pathways of microinvasive carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on high tumour-infiltrating lymphocytes.
Morita M; Yamaguchi R; Tanaka M; Tse GM; Yamaguchi M; Otsuka H; Kanomata N; Minami S; Eguchi S; Yano H
J Clin Pathol; 2016 Oct; 69(10):890-8. PubMed ID: 27030304
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H
Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673
[TBL] [Abstract][Full Text] [Related]
18. Lymphocyte-activating gene-3 expression is associated with tumor-infiltrating lymphocyte levels in HER2-positive breast cancers.
Lee S; Kim JY; Lee SJ; Kwon SW; Jung HJ; Jung SJ; Kim KB; Choi KU; Lee CH; Huh GY; Kim A
Medicine (Baltimore); 2021 Dec; 100(50):e28057. PubMed ID: 34918659
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
20. Higher densities of tumour-infiltrating lymphocytes and CD4
Thike AA; Chen X; Koh VCY; Binte Md Nasir ND; Yeong JPS; Bay BH; Tan PH
Histopathology; 2020 May; 76(6):852-864. PubMed ID: 31883279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]